查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1705432

2025年多種癌症早期檢測全球市場報告

Multi Cancer Early Detection Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年多種癌症早期檢測市場規模將快速成長。到 2029 年，這一數字將成長至 34.9 億美元，複合年成長率為 19.1%。預測期內的成長可歸因於遠端醫療健康的擴展、對預防性醫療保健的日益重視、精準腫瘤學的日益普及、生物標記發現的進步以及直接面對消費者的基因檢測的激增。預測期內的關鍵趨勢包括人工智慧和機器學習的使用日益增多、液態切片技術的採用日益增多、多組體學方法的整合、家用檢測套組的擴展、對早期癌症檢測的日益關注以及微創診斷方法的開發。

個人化醫療的日益普及將有助於未來擴大多種癌症早期檢測市場。個人化醫療是根據個人的特徵和基因組成客製化醫療干預措施，由於可以改善治療效果而越來越受歡迎。這一趨勢受到基因組學的進步、疾病複雜性的增加以及支持性法律規範的推動。個人化醫療透過根據個人的基因和生物標記情況客製化篩檢和治療方法，提高了多種癌症早期發現的有效性。例如，FDA 於 2024 年 2 月核准的針對罕見疾病的新型個人化治療方法的數量從 2022 年的 6 種增加到 16 種。因此，個人化醫療的接受度不斷提高正在推動多癌症早期檢測市場的成長。

多癌症早期檢測市場的主要企業正在創新基於 ctDNA 的液態切片測試，以提高敏感性、特異性和早期檢測率，最終帶來更好的患者治療效果。這些測試可檢測血液中的循環腫瘤 DNA，並提供一種非侵入性的方法來追蹤腫瘤動態、治療反應、早期復發和微量殘存疾病。例如，2023年5月，美國癌症診斷公司Lucence在其美國總部推出了開創性的多癌症早期檢測（MCED）血液測試LucenceINSIGHT。這種基於 ctDNA 的液態切片測試可以透過單一血液樣本篩檢10 種常見癌症類型。全球約 78% 的癌症死亡與沒有常規篩檢通訊協定的癌症類型有關，這种血液檢測為尋求篩檢多種癌症類型的無症狀人群提供了便利和更高的可及性。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場 - 宏觀經濟情景，包括利率、感染疾病、地緣政治、新冠疫情、經濟復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球多種癌症早期檢測PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球多種癌症早期檢測市場：成長率分析
  • 全球多癌種早期檢測市場表現：規模與成長，2019-2024
  • 全球多種癌症早期檢測市場預測：規模與成長，2024-2029 年，2034 年
  • 全球多種癌症早期檢測總目標市場（TAM）

第6章市場區隔

  • 全球多種癌症早期檢測市場（按類型、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 液態生物檢體
  • 基因面板
  • 實驗室檢查（LDT）
  • 其他類型
  • 全球多癌種早期檢測市場（依癌症類型、表現及預測）2019-2024 年、2024-2029 年及 2034 年
  • 固態腫瘤
  • 造血系統惡性腫瘤
  • 全球多癌種早期檢測市場：依最終用戶、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 診斷實驗室
  • 其他最終用戶
  • 全球多癌種早期檢測市場，依液態生物檢體類型細分，依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 循環性腫瘤細胞（CTC）
  • 循環腫瘤DNA（CtDNA）
  • 外泌體
  • 全球多癌種早期檢測市場、基因面板細分、類型、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 基於DNA的面板
  • 基於RNA的面板
  • 多基因面板
  • 全球多癌種早期檢測市場，按實驗室檢測 (LDT) 類型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
  • PCR檢測
  • 次世代定序（NGS）檢測
  • 免疫組織化學（IHC）測試
  • 全球多癌種早期檢測市場，按類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 蛋白質生物標記
  • 基於自身抗體的檢測

第7章 區域和國家分析

  • 全球多種癌症早期檢測市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球多癌種早期檢測市場：依國家/地區、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

  • 多癌種早期檢測市場：競爭格局
  • 多癌症早期檢測市場：公司簡介
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sysmex Inostics GmbH Overview, Products and Services, Strategy and Financial Analysis
    • Exact Sciences Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Natera Inc Overview, Products and Services, Strategy and Financial Analysis
    • Guardant Health Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • Core Diagnostics
  • Genecast Biotechnology Co. Ltd
  • Burning Rock Biotech Limited
  • Freenome Holdings Inc.
  • Guangzhou AnchorDx Medical Co. Ltd
  • Singlera Genomics Incorporated
  • Naveris Inc.
  • Lucence Health Inc.
  • PredOmix Technologies
  • Micronoma INC.
  • EarlyDiagnostics（EarlyDx）
  • Elypta AB
  • Predictive Oncology
  • ANPAC Bio-Medical Science Co. Ltd
  • CanSense Ltd

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029年多癌症早期檢測市場：提供新機會的國家
  • 2029年多癌種早期檢測市場：細分領域帶來新機會
  • 2029年多癌症早期檢測市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r30742

Multi-cancer early detection involves identifying and diagnosing various cancer types in their early stages through the examination of biomarkers and other indicators present in bodily fluids or tissues. The objective is to detect cancerous conditions affecting multiple organs or tissues before symptoms appear, thereby facilitating prompt intervention and enhancing treatment effectiveness.

The primary categories of multi-cancer early detection include liquid biopsy, gene panels, laboratory-developed tests (LDT), and other methodologies. Liquid biopsy, for instance, is a non-invasive diagnostic procedure that identifies cancer-related biomarkers, such as circulating tumor cells (CTCs) or cell-free DNA (cfDNA), from bodily fluids such as blood or urine. These tests provide valuable information on cancer detection, progression, and response to treatment. They are utilized across hospitals, diagnostic facilities, and other medical settings for diagnosing various cancer types, including both solid tumors and hematological malignancies.

The multi cancer early detection market research report is one of a series of new reports from The Business Research Company that provides multi cancer early detection market statistics, including the multi cancer early detection industry global market size, regional shares, competitors with multi cancer early detection market share, detailed multi cancer early detection market segments, market trends, and opportunities, and any further data you may need to thrive in the multi cancer early detection industry. This multi cancer early detection market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multi cancer early detection market size has grown rapidly in recent years. It will grow from $1.45 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to increasing prevalence of cancer, government initiatives and funding, growing awareness about early cancer detection, expansion of healthcare infrastructure, rising adoption of personalized medicine, decreasing costs of genetic testing.

The multi cancer early detection market size is expected to see rapid growth in the next few years. It will grow to $3.49 billion in 2029 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to expansion of telemedicine and digital health, growing emphasis on preventive healthcare, increasing adoption of precision oncology, advances in biomarker discovery, surge in direct-to-consumer genetic testing. Major trends in the forecast period include increasing use of AI and machine learning, growing adoption of liquid biopsy techniques, integration of multi-omics approaches, expansion of at-home testing kits, rising focus on early-stage cancer detection, development of minimally invasive diagnostics.

The increasing adoption of personalized medicine is poised to drive the expansion of the multi-cancer early detection market in the future. Personalized medicine, which customizes healthcare interventions based on individual characteristics and genetic makeup, is gaining traction due to its ability to enhance treatment efficacy. This trend is fueled by advancements in genomics, the growing complexity of diseases, and supportive regulatory frameworks. Personalized medicine amplifies the effectiveness of multi-cancer early detection by tailoring screening and treatment approaches to individual genetic and biomarker profiles. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases, up from six in 2022, including seven cancer treatments and three for various other conditions, as reported by the Personalized Medicine Coalition. Hence, the increasing embrace of personalized medicine is fostering growth in the multi-cancer early detection market.

Major companies in the multi-cancer early detection market are innovating ctDNA-based liquid biopsy tests to improve sensitivity, specificity, and early detection rates, ultimately enhancing patient outcomes. These tests detect circulating tumor DNA in the bloodstream, offering a non-invasive method to track tumor dynamics, treatment response, and early recurrence or minimal residual disease. For example, in May 2023, Lucence, a US-based cancer diagnostics firm, unveiled LucenceINSIGHT, a pioneering multi-cancer early detection (MCED) blood test, at their US headquarters. This ctDNA-based liquid biopsy test enables screening for 10 common cancers using a single blood sample. With approximately 78% of global cancer deaths linked to types lacking routine screening protocols, this blood test offers improved convenience and accessibility for asymptomatic individuals seeking screening for various cancer types.

In May 2023, Freenome Holdings Inc., a US-based biotechnology company, acquired Oncimmune Ltd. for an undisclosed sum. This acquisition is aimed at enhancing Freenome's early cancer detection capabilities by incorporating Oncimmune's autoantibody platform and expanding its multiomics portfolio. Oncimmune Ltd., a UK-based biotechnology firm, specializes in immunodiagnostics for cancer detection.

Major companies operating in the multi cancer early detection market are Illumina Inc., Sysmex Inostics GmbH, Exact Sciences Corporation, Natera Inc, Guardant Health, Core Diagnostics, Genecast Biotechnology Co. Ltd, Burning Rock Biotech Limited, Freenome Holdings Inc., Guangzhou AnchorDx Medical Co. Ltd, Singlera Genomics Incorporated, Naveris Inc. , Lucence Health Inc., PredOmix Technologies, Micronoma INC., EarlyDiagnostics (EarlyDx), Elypta AB, Predictive Oncology, ANPAC Bio-Medical Science Co. Ltd, CanSense Ltd, Epigenomics AG, VolitionRX, OncoSeek, Laboratory for Advanced Medicine, Inc., AnchorDx

North America was the largest region in the multi cancer early detection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multi cancer early detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multi cancer early detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multi-cancer early detection market consists of revenues earned by entities by providing services such as diagnostic imaging, screening tests, molecular diagnostics, and risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multi-cancer early detection market also includes sales of assay panels, diagnostic kits, reagents, instruments, software solutions for data analysis and interpretation, and quality control materials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multi Cancer Early Detection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multi cancer early detection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multi cancer early detection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multi cancer early detection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Liquid Biopsy; Gene Panel; Laboratory Developed Tests (LDT); Other Types
  • 2) By Cancer Type: Solid Tumors; Hematological Malignancies
  • 3) By End-User: Hospitals; Diagnostic Laboratories; Other End Users
  • Subsegments:
  • 1) By Liquid Biopsy Types: Circulating Tumor Cells (CTC); Circulating Tumor DNA (Ctdna); Exosomes
  • 2) By Gene Panel: DNA-Based Panels; RNA-Based Panels; Multi-Gene Panels
  • 3) By Laboratory Developed Tests (LDT): PCR-Based Tests; Next-Generation Sequencing (NGS) Tests; Immunohistochemistry (IHC) Tests
  • 4) By Other Types: Protein Biomarkers; Autoantibody-Based Tests
  • Companies Mentioned: Illumina Inc.; Sysmex Inostics GmbH; Exact Sciences Corporation; Natera Inc; Guardant Health
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multi Cancer Early Detection Market Characteristics

3. Multi Cancer Early Detection Market Trends And Strategies

4. Multi Cancer Early Detection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Multi Cancer Early Detection Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Multi Cancer Early Detection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Multi Cancer Early Detection Market Growth Rate Analysis
  • 5.4. Global Multi Cancer Early Detection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Multi Cancer Early Detection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Multi Cancer Early Detection Total Addressable Market (TAM)

6. Multi Cancer Early Detection Market Segmentation

  • 6.1. Global Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Liquid Biopsy
  • Gene Panel
  • Laboratory Developed Tests (LDT)
  • Other Types
  • 6.2. Global Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Solid Tumors
  • Hematological Malignancies
  • 6.3. Global Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Laboratories
  • Other End Users
  • 6.4. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Liquid Biopsy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Circulating Tumor Cells (CTC)
  • Circulating Tumor DNA (Ctdna)
  • Exosomes
  • 6.5. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Gene Panel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA-Based Panels
  • RNA-Based Panels
  • Multi-Gene Panels
  • 6.6. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Laboratory Developed Tests (LDT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR-Based Tests
  • Next-Generation Sequencing (NGS) Tests
  • Immunohistochemistry (IHC) Tests
  • 6.7. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Protein Biomarkers
  • Autoantibody-Based Tests

7. Multi Cancer Early Detection Market Regional And Country Analysis

  • 7.1. Global Multi Cancer Early Detection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Multi Cancer Early Detection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multi Cancer Early Detection Market

  • 8.1. Asia-Pacific Multi Cancer Early Detection Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multi Cancer Early Detection Market

  • 9.1. China Multi Cancer Early Detection Market Overview
  • 9.2. China Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multi Cancer Early Detection Market

  • 10.1. India Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multi Cancer Early Detection Market

  • 11.1. Japan Multi Cancer Early Detection Market Overview
  • 11.2. Japan Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multi Cancer Early Detection Market

  • 12.1. Australia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multi Cancer Early Detection Market

  • 13.1. Indonesia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multi Cancer Early Detection Market

  • 14.1. South Korea Multi Cancer Early Detection Market Overview
  • 14.2. South Korea Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multi Cancer Early Detection Market

  • 15.1. Western Europe Multi Cancer Early Detection Market Overview
  • 15.2. Western Europe Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multi Cancer Early Detection Market

  • 16.1. UK Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multi Cancer Early Detection Market

  • 17.1. Germany Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multi Cancer Early Detection Market

  • 18.1. France Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multi Cancer Early Detection Market

  • 19.1. Italy Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multi Cancer Early Detection Market

  • 20.1. Spain Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multi Cancer Early Detection Market

  • 21.1. Eastern Europe Multi Cancer Early Detection Market Overview
  • 21.2. Eastern Europe Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multi Cancer Early Detection Market

  • 22.1. Russia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multi Cancer Early Detection Market

  • 23.1. North America Multi Cancer Early Detection Market Overview
  • 23.2. North America Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multi Cancer Early Detection Market

  • 24.1. USA Multi Cancer Early Detection Market Overview
  • 24.2. USA Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multi Cancer Early Detection Market

  • 25.1. Canada Multi Cancer Early Detection Market Overview
  • 25.2. Canada Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multi Cancer Early Detection Market

  • 26.1. South America Multi Cancer Early Detection Market Overview
  • 26.2. South America Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multi Cancer Early Detection Market

  • 27.1. Brazil Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multi Cancer Early Detection Market

  • 28.1. Middle East Multi Cancer Early Detection Market Overview
  • 28.2. Middle East Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multi Cancer Early Detection Market

  • 29.1. Africa Multi Cancer Early Detection Market Overview
  • 29.2. Africa Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multi Cancer Early Detection Market Competitive Landscape And Company Profiles

  • 30.1. Multi Cancer Early Detection Market Competitive Landscape
  • 30.2. Multi Cancer Early Detection Market Company Profiles
    • 30.2.1. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Sysmex Inostics GmbH Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Exact Sciences Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Natera Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Guardant Health Overview, Products and Services, Strategy and Financial Analysis

31. Multi Cancer Early Detection Market Other Major And Innovative Companies

  • 31.1. Core Diagnostics
  • 31.2. Genecast Biotechnology Co. Ltd
  • 31.3. Burning Rock Biotech Limited
  • 31.4. Freenome Holdings Inc.
  • 31.5. Guangzhou AnchorDx Medical Co. Ltd
  • 31.6. Singlera Genomics Incorporated
  • 31.7. Naveris Inc.
  • 31.8. Lucence Health Inc.
  • 31.9. PredOmix Technologies
  • 31.10. Micronoma INC.
  • 31.11. EarlyDiagnostics (EarlyDx)
  • 31.12. Elypta AB
  • 31.13. Predictive Oncology
  • 31.14. ANPAC Bio-Medical Science Co. Ltd
  • 31.15. CanSense Ltd

32. Global Multi Cancer Early Detection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multi Cancer Early Detection Market

34. Recent Developments In The Multi Cancer Early Detection Market

35. Multi Cancer Early Detection Market High Potential Countries, Segments and Strategies

  • 35.1 Multi Cancer Early Detection Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Multi Cancer Early Detection Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Multi Cancer Early Detection Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer